AR040548A1 - Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria ( pacap) y sus metodos de uso farmacologicos - Google Patents
Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria ( pacap) y sus metodos de uso farmacologicosInfo
- Publication number
- AR040548A1 AR040548A1 AR20030102511A ARP030102511A AR040548A1 AR 040548 A1 AR040548 A1 AR 040548A1 AR 20030102511 A AR20030102511 A AR 20030102511A AR P030102511 A ARP030102511 A AR P030102511A AR 040548 A1 AR040548 A1 AR 040548A1
- Authority
- AR
- Argentina
- Prior art keywords
- vpac2
- peptides
- hypofisary
- cyclass
- pacap
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 title abstract 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 title 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 229920001184 polypeptide Polymers 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39573802P | 2002-07-12 | 2002-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040548A1 true AR040548A1 (es) | 2005-04-13 |
Family
ID=30115918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102511A AR040548A1 (es) | 2002-07-12 | 2003-07-11 | Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria ( pacap) y sus metodos de uso farmacologicos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7378494B2 (enExample) |
| EP (1) | EP1578358A2 (enExample) |
| JP (1) | JP2006506969A (enExample) |
| CN (1) | CN101405298A (enExample) |
| AR (1) | AR040548A1 (enExample) |
| AU (1) | AU2003267990A1 (enExample) |
| BR (1) | BR0312621A (enExample) |
| CA (1) | CA2491279A1 (enExample) |
| DO (1) | DOP2003000669A (enExample) |
| GT (1) | GT200300142A (enExample) |
| HN (1) | HN2003000217A (enExample) |
| IL (1) | IL165499A (enExample) |
| MX (1) | MXPA04012305A (enExample) |
| PE (1) | PE20040677A1 (enExample) |
| PL (1) | PL377025A1 (enExample) |
| RU (1) | RU2360922C2 (enExample) |
| TW (1) | TW200409641A (enExample) |
| UY (1) | UY27893A1 (enExample) |
| WO (1) | WO2004006839A2 (enExample) |
| ZA (1) | ZA200501118B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301431D0 (sv) * | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
| US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| EP1713493A4 (en) * | 2004-01-27 | 2009-06-24 | Bayer Pharmaceuticals Corp | PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS |
| US20080096811A1 (en) * | 2004-05-21 | 2008-04-24 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2564740A1 (en) * | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| WO2005119524A2 (en) | 2004-06-04 | 2005-12-15 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
| EP1768686A4 (en) * | 2004-06-12 | 2007-11-14 | Bayer Pharmaceuticals Corp | PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE |
| CA2577010A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US20080085860A1 (en) * | 2004-08-18 | 2008-04-10 | Eli Lilly And Company | Selective Vpac2 Receptor Peptide Agonists |
| US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
| US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| US20070293429A1 (en) * | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| WO2006042152A2 (en) | 2004-10-08 | 2006-04-20 | Forbes Medi-Tech (Research) Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| US20080214440A1 (en) * | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| US20060159737A1 (en) * | 2004-11-19 | 2006-07-20 | Steffen Panzner | Pharmaceutical compositions for local administration |
| ATE432322T1 (de) * | 2004-12-21 | 2009-06-15 | Lubrizol Ltd | Zusammensetzungen |
| WO2006110551A2 (en) * | 2005-04-08 | 2006-10-19 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
| EP1915393A1 (en) * | 2005-08-11 | 2008-04-30 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US7582608B2 (en) * | 2005-10-26 | 2009-09-01 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
| BRPI0708341A2 (pt) * | 2006-02-28 | 2011-05-24 | Lilly Co Eli | agonistas peptìdicos seletivos do receptor vpac2 |
| EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
| DK2321640T3 (en) * | 2008-08-21 | 2017-02-27 | Immunogenics Llc | FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| CN106794217A (zh) * | 2014-08-06 | 2017-05-31 | 血管生物科学 | 包含对患病组织具有选择性的药效团的组合物及其制备方法 |
| TWI721976B (zh) | 2015-04-16 | 2021-03-21 | 美商艾爾德生物製藥股份有限公司 | 抗ｐａｃａｐ抗體及其用途 |
| EP3426288A4 (en) | 2016-04-15 | 2019-10-30 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972319B1 (en) * | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
-
2003
- 2003-07-11 JP JP2004521702A patent/JP2006506969A/ja active Pending
- 2003-07-11 PL PL377025A patent/PL377025A1/pl unknown
- 2003-07-11 CA CA002491279A patent/CA2491279A1/en not_active Abandoned
- 2003-07-11 MX MXPA04012305A patent/MXPA04012305A/es unknown
- 2003-07-11 EP EP03748938A patent/EP1578358A2/en not_active Withdrawn
- 2003-07-11 WO PCT/US2003/021761 patent/WO2004006839A2/en not_active Ceased
- 2003-07-11 AR AR20030102511A patent/AR040548A1/es unknown
- 2003-07-11 CN CNA038166445A patent/CN101405298A/zh active Pending
- 2003-07-11 DO DO2003000669A patent/DOP2003000669A/es unknown
- 2003-07-11 GT GT200300142A patent/GT200300142A/es unknown
- 2003-07-11 RU RU2005103396/13A patent/RU2360922C2/ru not_active IP Right Cessation
- 2003-07-11 BR BR0312621-8A patent/BR0312621A/pt not_active IP Right Cessation
- 2003-07-11 HN HN2003000217A patent/HN2003000217A/es unknown
- 2003-07-11 PE PE2003000697A patent/PE20040677A1/es not_active Application Discontinuation
- 2003-07-11 AU AU2003267990A patent/AU2003267990A1/en not_active Abandoned
- 2003-07-11 UY UY27893A patent/UY27893A1/es not_active Application Discontinuation
- 2003-07-11 US US10/618,126 patent/US7378494B2/en not_active Expired - Fee Related
- 2003-07-11 TW TW092118986A patent/TW200409641A/zh unknown
-
2004
- 2004-12-01 IL IL165499A patent/IL165499A/en not_active IP Right Cessation
-
2005
- 2005-02-08 ZA ZA200501118A patent/ZA200501118B/en unknown
-
2008
- 2008-05-23 US US12/154,468 patent/US20090258826A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GT200300142A (es) | 2004-03-17 |
| HN2003000217A (es) | 2004-07-26 |
| MXPA04012305A (es) | 2005-02-25 |
| RU2005103396A (ru) | 2005-09-20 |
| US20090258826A1 (en) | 2009-10-15 |
| IL165499A (en) | 2010-12-30 |
| RU2360922C2 (ru) | 2009-07-10 |
| UY27893A1 (es) | 2003-12-31 |
| DOP2003000669A (es) | 2004-01-31 |
| CN101405298A (zh) | 2009-04-08 |
| EP1578358A2 (en) | 2005-09-28 |
| US20040058870A1 (en) | 2004-03-25 |
| ZA200501118B (en) | 2006-08-30 |
| IL165499A0 (en) | 2006-01-15 |
| PE20040677A1 (es) | 2004-10-29 |
| TW200409641A (en) | 2004-06-16 |
| CA2491279A1 (en) | 2004-01-22 |
| US7378494B2 (en) | 2008-05-27 |
| JP2006506969A (ja) | 2006-03-02 |
| WO2004006839A2 (en) | 2004-01-22 |
| AU2003267990A1 (en) | 2004-02-02 |
| PL377025A1 (pl) | 2006-01-23 |
| BR0312621A (pt) | 2005-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040548A1 (es) | Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria ( pacap) y sus metodos de uso farmacologicos | |
| MY131983A (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use | |
| EP3080150B1 (en) | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists | |
| EP3080154B1 (en) | Dual glp-1/gip receptor agonists | |
| US8222217B2 (en) | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders | |
| US20170022260A9 (en) | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists | |
| US20150166625A1 (en) | Exendin-4 Peptide Analogues | |
| DK0699686T3 (da) | Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid | |
| EP3080149A1 (en) | Dual glp-1/glucagon receptor agonists | |
| JP2017512800A (ja) | エキセンジン−４に由来するペプチド二重ｇｌｐ−１／グルカゴン受容体アゴニスト | |
| JP2017517483A (ja) | エキセンジン−４に由来する二重ｇｌｐ−１／グルカゴン受容体アゴニスト | |
| AU2016292747A1 (en) | New exendin-4 derivatives as selective peptidic dual GLP-1 / glucagon receptor agonists | |
| KR20160142322A (ko) | 펩티드 이중 glp-1/글루카곤 수용체 효능제로서의 엑센딘-4 유도체 | |
| JP2016506401A (ja) | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 | |
| KR20120062777A (ko) | 변형된 혈관활성 장 펩티드 | |
| WO2014113434A1 (en) | Therapeutic agents, compositions, and methods for glycemic control | |
| EP1641824B1 (en) | Relaxin superfamily peptide analogues | |
| WO2016198604A1 (en) | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists | |
| KR20170106373A (ko) | 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체 | |
| Shimon et al. | Structure and function of somatostatin receptors in growth hormone control | |
| WO2005072385A3 (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | |
| TW200716156A (en) | Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use | |
| ECSP003683A (es) | Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico | |
| TH84721A (th) | อะโกนิสต์ของตัวรับ (vpac2) ของเปปไตด์ที่กระตุ้นปิตูอิตารี่อะดีนิเลตไซเดลส (pacap) และการใช้วิธีการทางเภสัชวิทยาของมัน | |
| RU2021115748A (ru) | Фрагменты пептидов для лечения диабета |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |